Somatopsychic Phenotype of the Bronchial Asthma: Diagnostics and Treatment

The investigation is devoted to the problem of improvement of diagnostics and treatment of the somatopsychic phenotype (SPPh) at patients with bronchial asthma (BA). On the basis of complex clinical, instrumental, psychological inspection, investigation of the parameters of life quality by MOS SF-36 questionnaire of 207 BA-patients certain prevalence of the combination of concomitant psycho-emotional disorders in 39.1% of BA patients, such as high levels of anxiety, neurotism, clinically significant depressive symptoms and somatopsychological accentuations (pedantry, emotionality, anxiety, excitability, cyclothymia and dysthymia). It is established, that BA patients have the somatopsychic phenotype of the course of the disease. We described the features of clinical course of BA, lung functional parameters and indexes of quality of life at patients with the pathologically changed somatopsychological descriptions. It is associated with an increase in the clinical severity of the disease, a decrease in the lung function parameters, low quality of life indexes and absence of asthma control. Assignment of psychotropic drugs (fabomotisol dihydrochloride (afobazole) or piracetam/thiotriazoline) in the complex treatment leads to stabilization of the clinical and psychological state of patients, increasing the level of control of asthma. The clinical and economic effectiveness of using of the combined modes of therapy with including of preparations of psychotropic action on a base treatment was proved.